[19] The effective dose is found by titration of the medication until symptoms are ... better medications are available for the overactive bladder. With the recent approval of tolterodine and ...

for the treatment of overactive bladder (OAB).This is the first time that CTAF has addressed this topic.

Frequent urination often signals underlying health conditions that require medical attention. While occasional increases in ...

It is clearly effective in increasing bladder capacity, but the impacts on bedwetting are less certain with mixed results in research studies. It might be a useful adjunctive therapy to other ...

Treatments for mental health conditions are structured around the condition being treated and typically are holistic in nature- including not just medication but also other interventions, such as ...

Sign In We don’t recognize that sign in. Your username maybe be your email address. Passwords are 6-20 characters with at least one number and letter. We still don’t recognize that sign in.

or if you are taking an anticholinergic medication (used to manage brain, bladder, and digestive conditions), such as Benadryl (diphenhydramine) or Oxytrol (oxybutynin). Cyclobenzaprine should not be ...

Oct. 15, 2024 — A team tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human prostate cancer ...

Drug diversion is the channelling of prescription drugs from a medical source into the illegal market. The problem is growing as abuse of prescription treatments, such as opioids, stimulants ...

Oct. 9, 2024 — A new study has found some cancers to be slightly more frequent in people with multiple sclerosis (MS) than in people without MS. Types of cancers found to have a small increased ...

Our expert, award-winning staff selects the products we cover and rigorously researches and tests our top picks. If you buy through our links, we may get a commission. Reviews ethics statement ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), today announced the first patient has been randomized and dosed in a Phase 2 clinical study evaluating sunobinop ...